-
1
-
-
40649090312
-
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
-
Boeck S., Wilkowski R., Bruns C.J., et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73 3-4 (2007) 221-227
-
(2007)
Oncology
, vol.73
, Issue.3-4
, pp. 221-227
-
-
Boeck, S.1
Wilkowski, R.2
Bruns, C.J.3
-
2
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 6 (1997) 2403-2413
-
(1997)
J. Clin. Oncol.
, vol.15
, Issue.6
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
-
3
-
-
0036137690
-
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
-
Cartwright T.H., Cohn A., Varkey J.A., et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 20 1 (2002) 160-164
-
(2002)
J. Clin. Oncol.
, vol.20
, Issue.1
, pp. 160-164
-
-
Cartwright, T.H.1
Cohn, A.2
Varkey, J.A.3
-
4
-
-
33646529151
-
Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden
-
Davison S.N., Jhangri G.S., and Johnson J.A. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int. 69 9 (2006) 1621-1625
-
(2006)
Kidney Int.
, vol.69
, Issue.9
, pp. 1621-1625
-
-
Davison, S.N.1
Jhangri, G.S.2
Johnson, J.A.3
-
5
-
-
0037302385
-
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer
-
Farrell M.P., and Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 2 4 (2003) 253-256
-
(2003)
Clin. Colorectal Cancer
, vol.2
, Issue.4
, pp. 253-256
-
-
Farrell, M.P.1
Kummar, S.2
-
6
-
-
75249096497
-
Incidence of diarrhea in patients with GI malignancies treated with PHY906 and capecitabine (CAP) 7/7
-
Abstract
-
Hoimes C., Podoltsev N., Lamb L., Ruta S., Mezes M., Elligers K., Grant N., Liu S., Cheng Y., Saif M.W. Incidence of diarrhea in patients with GI malignancies treated with PHY906 and capecitabine (CAP) 7/7. 2009 Gastrointestinal Cancers Symposium; Abstract # 172.
-
(2009)
Gastrointestinal Cancers Symposium
, Issue.172
-
-
Hoimes, C.1
Podoltsev, N.2
Lamb, L.3
Ruta, S.4
Mezes, M.5
Elligers, K.6
Grant, N.7
Liu, S.8
Cheng, Y.9
Saif, M.W.10
-
7
-
-
33846457870
-
Cancer statistics, 2007
-
Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 1 (2007) 43-66
-
(2007)
CA Cancer J. Clin.
, vol.57
, Issue.1
, pp. 43-66
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Thun, M.J.6
-
8
-
-
0012734882
-
Chinese medicine formulation, PHY-906, can enhance the therapeutic Index of CPT-11 and other anticancer drugs against cancer in mice
-
Liu S.-H., Jiang Z., and Cheng Y.-C.A. Chinese medicine formulation, PHY-906, can enhance the therapeutic Index of CPT-11 and other anticancer drugs against cancer in mice. Proc. Am. Assoc. Cancer Res. 42 85 (2001) 458
-
(2001)
Proc. Am. Assoc. Cancer Res.
, vol.42
, Issue.85
, pp. 458
-
-
Liu, S.-H.1
Jiang, Z.2
Cheng, Y.-C.A.3
-
9
-
-
71949100830
-
PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer
-
Liu S.-H., Jiang Z., Gao W., et al., PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer. In: Proc. Am. Soc. Clin. Oncol. 2003;Abstr #864.
-
Proc. Am. Soc. Clin. Oncol. 2003;Abstr
, Issue.864
-
-
Liu, S.-H.1
Jiang, Z.2
Gao, W.3
-
10
-
-
75249100435
-
PHY906: Enhancement of Cancer Chemotherapeutic Agents and Insights into Mechanism of Action
-
Liu S.-H., Jiang Z., Leung D., Lee Y., and Cheng Y. PHY906: Enhancement of Cancer Chemotherapeutic Agents and Insights into Mechanism of Action. Proc. "Med. 21st Century Tri-Conf. Bio-Forum (2004) 77
-
(2004)
Proc. "Med. 21st Century Tri-Conf. Bio-Forum
, pp. 77
-
-
Liu, S.-H.1
Jiang, Z.2
Leung, D.3
Lee, Y.4
Cheng, Y.5
-
11
-
-
3042524200
-
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
-
Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 1 (2004) 133-138
-
(2004)
Cancer
, vol.101
, Issue.1
, pp. 133-138
-
-
Milella, M.1
Gelibter, A.2
Di Cosimo, S.3
-
12
-
-
33745787917
-
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial.
-
Mitry E., Ducreux M., Ould-Kaci M., et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial. Gastroenterol. Clin. Biol. 30 3 (2006) 357-363
-
(2006)
Gastroenterol. Clin. Biol.
, vol.30
, Issue.3
, pp. 357-363
-
-
Mitry, E.1
Ducreux, M.2
Ould-Kaci, M.3
-
13
-
-
31044440384
-
Edmonton symptom assessment scale: Italian validation in two palliative care settings
-
Moro C., Brunelli C., Miccinesi G., et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14 1 (2006) 30-37
-
(2006)
Support Care Cancer
, vol.14
, Issue.1
, pp. 30-37
-
-
Moro, C.1
Brunelli, C.2
Miccinesi, G.3
-
14
-
-
33646783722
-
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (Publish date
-
National Cancer Institute U.S. National Institute of Health, August 9
-
National Cancer Institute U.S. National Institute of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (Publish date August 9, 2006).
-
(2006)
-
-
-
15
-
-
58749093918
-
CONKO-1: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer
-
(May 20 suppl, LBA4504)
-
Neuhaus P., Riess H., Post S., et al. CONKO-1: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer. JCO 26 (2008) (May 20 suppl, LBA4504)
-
(2008)
JCO
, vol.26
-
-
Neuhaus, P.1
Riess, H.2
Post, S.3
-
16
-
-
75249086214
-
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma
-
Saif M.W., Liu S., Elfiky A., Jiang Z., and Cheng Y. Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. J. Clin. Oncol. 25 18S (2007) 15116
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18 S
, pp. 15116
-
-
Saif, M.W.1
Liu, S.2
Elfiky, A.3
Jiang, Z.4
Cheng, Y.5
-
17
-
-
48949099568
-
Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008
-
Saif M.W. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008. JOP 9 4 (2008) 403-407
-
(2008)
JOP
, vol.9
, Issue.4
, pp. 403-407
-
-
Saif, M.W.1
-
18
-
-
0037837645
-
Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
-
Scheithauer W., Kornek G.V., Raderer M., et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 21 7 (2003) 1307-1312
-
(2003)
J. Clin. Oncol.
, vol.21
, Issue.7
, pp. 1307-1312
-
-
Scheithauer, W.1
Kornek, G.V.2
Raderer, M.3
-
19
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
-
(2000)
J. Natl. Cancer Inst.
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
20
-
-
42949171085
-
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
-
Traina T.A., Theodoulou M., Feigin K., et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J. Clin. Oncol. 26 11 (2008) 1797-1802
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.11
, pp. 1797-1802
-
-
Traina, T.A.1
Theodoulou, M.2
Feigin, K.3
-
21
-
-
22144433634
-
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a Phase II study
-
Tsavaris N., Kosmas C., Skopelitis H., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a Phase II study. Invest. New Drugs 23 4 (2005) 369-375
-
(2005)
Invest. New Drugs
, vol.23
, Issue.4
, pp. 369-375
-
-
Tsavaris, N.1
Kosmas, C.2
Skopelitis, H.3
-
22
-
-
33646531836
-
The Edmonton Symptom Assessment System as a screening tool for depression and anxiety
-
Vignaroli E., Pace E.A., Willey J., Palmer J.L., Zhang T., and Bruera E. The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J. Palliat. Med. 9 2 (2006) 296-303
-
(2006)
J. Palliat. Med.
, vol.9
, Issue.2
, pp. 296-303
-
-
Vignaroli, E.1
Pace, E.A.2
Willey, J.3
Palmer, J.L.4
Zhang, T.5
Bruera, E.6
-
23
-
-
75249091102
-
Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma
-
(May 20 suppl; abstr 4610)
-
Yen Y., So S., Rose M., et al. Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr 4610)
-
(2008)
J. Clin. Oncol.
, vol.26
-
-
Yen, Y.1
So, S.2
Rose, M.3
|